...
首页> 外文期刊>Gut: Journal of the British Society of Gastroenterology >A disrupted RNA editing balance mediated by ADARs (Adenosine DeAminases that act on RNA) in human hepatocellular carcinoma
【24h】

A disrupted RNA editing balance mediated by ADARs (Adenosine DeAminases that act on RNA) in human hepatocellular carcinoma

机译:人类肝细胞癌中由ADARs(作用于RNA的腺苷脱氨酶)介导的RNA编辑平衡被破坏

获取原文
获取原文并翻译 | 示例
           

摘要

Objective: Hepatocellular carcinoma (HCC) is a heterogeneous tumour displaying a complex variety of genetic and epigenetic changes. In human cancers, aberrant post-transcriptional modifications, such as alternative splicing and RNA editing, may lead to tumour specific transcriptome diversity. Design: By utilising large scale transcriptome sequencing of three paired HCC clinical specimens and their adjacent non-tumour (NT) tissue counterparts at depth, we discovered an average of 20 007 inferred A to I (adenosine to inosine) RNA editing events in transcripts. The roles of the double stranded RNA specific ADAR (Adenosine DeAminase that act on RNA) family members (ADARs) and the altered gene specific editing patterns were investigated in clinical specimens, cell models and mice. Results: HCC displays a severely disrupted A to I RNA editing balance. ADAR1 and ADAR2 manipulate the A to I imbalance of HCC via their differential expression in HCC compared with NT liver tissues. Patients with ADAR1 overexpression and ADAR2 downregulation in tumours demonstrated an increased risk of liver cirrhosis and postoperative recurrence and had poor prognoses. Due to the differentially expressed ADAR1 and ADAR2 in tumours, the altered gene specific editing activities, which was reflected by the hyper-editing of FLNB (filamin B, β) and the hypo-editing of COPA (coatomer protein complex, subunit α), are closely associated with HCC pathogenesis. In vitro and in vivo functional assays prove that ADAR1 functions as an oncogene while ADAR2 has tumour suppressive ability in HCC. Conclusions: These findings highlight the fact that the differentially expressed ADARs in tumours, which are responsible for an A to I editing imbalance, has great prognostic value and diagnostic potential for HCC.
机译:目的:肝细胞癌(HCC)是一种异质性肿瘤,表现出复杂的遗传和表观遗传学变化。在人类癌症中,异常的转录后修饰,例如选择性剪接和RNA编辑,可能导致肿瘤特异性转录组多样性。设计:通过对三对HCC临床标本及其相邻的非肿瘤(NT)组织对应物进行深度转录组测序,我们在转录本中平均发现了20 007个推断的A至I(腺苷至肌苷)RNA编辑事件。在临床标本,细胞模型和小鼠中,研究了双链RNA特异性ADAR(作用于RNA的腺苷脱氨酶)家族成员(ADAR)的作用以及基因特异性编辑模式的改变。结果:HCC显示出严重破坏的A至I RNA编辑平衡。与NT肝组织相比,ADAR1和ADAR2通过在肝癌中的差异表达来控制肝癌的A到I不平衡。肿瘤中ADAR1过表达和ADAR2下调的患者表现出肝硬化和术后复发的风险增加,并且预后不良。由于肿瘤中ADAR1和ADAR2差异表达,因此基因特异性编辑活性发生了变化,这反映在FLNB(丝氨酸蛋白B,β)的过度编辑和COPA(外套蛋白复合物,α亚基)的过度编辑中,与肝癌的发病机制密切相关。体外和体内功能测定证明,ADAR1可作为癌基因发挥作用,而ADAR2在HCC中具有肿瘤抑制能力。结论:这些发现凸显了这样一个事实,即在肿瘤中差异表达的ADAR导致A至I编辑失衡,对肝癌具有巨大的预后价值和诊断潜力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号